Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Oxb seems to have support around the £8 level. Still a lot of very odd single and low digit trades going through ! Concerned that this is going to drop again.. hope not..
Hi Seaking,
In the short term, like you, I think the markets are still quite volatile. I have some banks and Aviva which are trucking along on the back of the interest rate rise but Oxb could go either way. Some financial news on the vaccine might bolster the sp but is unlikely to be released.
My funds have taken a dip but it’s taken years to get them into Isa wrapper so loathed to sell. Drip feed in monthly as well so should come good again. Down on average 10%. Could be worse, keep well.
Hi, on the positive side the rest of the markets are having a bit of a correction . That said who knows if it will go up or down my gut feeling is the markets may well drop a good bit more on any negative news . I am holding awe,volex and Darktrace which have all been hammered.
Lloyds and barc which will be fine over the coming year gsk for the split .
Funds I sold the lot a few weeks ago so that’s one saving grace. Now that I’m with AJ Bell I will prob start buying funds over the next 3 months , going defensive income and infrastructure.
Hope you are all ok and haven’t been zapped too much . Just a matter of trying to ride out the storm. :-).
Half expected this to be sub £8 this morning which is my selling point. The last tranche has a £4.60 average so a profit is a profit. Looking forward I’m just not sure in the short to medium term what is going to drive this towards the previous highs.
More debt and increased cash burn. Sorry to hear about SAR. The aim can be very unforgiving.
Hindsight is wonderful. Selling at £15 would have been great but I almost always hang on too long and I am still kicking myself for believing the bottom was in the high 9s. Am going though a similar experience with SAR - down 60% from its high (didn't sell) and now looking for a 1:50 consolidation (sounds familiar?) as that will enable other institutional investors to participate. Down 10% today on the news and most LTH don't like the idea but I guess they have the votes in the bag as otherwise they wouldn't have floated it.
One day I will learn. Still have too much invested in OXB but am not selling at this price.
Hi Kern,
That was a big drop today. Should have dumped the remainder of my holding on the bounce. Hindsight ! Who would ever have imagined, for whatever reason, the sp would be sitting at this level, back to placing price. Only have a small holding left now but will have to reconsider my position here. See what tomorrow brings. G.L
This isn't even the right price. It is at 809 - just below the placing price. Not a good sign.
or it could be the market has only just woken us to the latest RNS and doesn't like it one bit.
Befuddled and disillusioned with the usual silence from the BOD.
I can only imagine the CEO leaving has cast a shadow on this deal. There appears to be cash in the bank, and more coming from the vaccine, but Oxb are instead borrowing to pay for Homology, a loss making company. This has perhaps given the market the jitters. Running before they can walk! I would have liked to have seen Oxb bank some money for a rainy day instead of taking on debt. Just my musings but a few months may make all the difference. Just where the sp goes in the meantime is anyones guess.
Hopefully the next set of results will be very encouraging. In May, the Group announced that AstraZeneca had committed to an increase in the number of batches required from Oxford Biomedica in the second half of 2021. This resulted in the Group raising its expectation for cumulative revenues from the contract to be in excess of £100 million by the end of 2021.
Not sure what cash they have to hand now but it could be a while before they turn Homology to profit. That said the Astra contract could go for years generating massive returns making this purchase insignificant.
Saw my dentist yesterday only to be called this morning as she has now tested positive. Fingers crossed.
Better than it was. Another £1 and I will be even on my last purchase. It is really hard to see what that RNS means going forward. I will try to do some calculations on cash in hand and monthly burn but the figures are quite opaque so I am not hopeful.
Maybe spoke too soon.
Going in the right direction for a change;-)
859p to sell so no negative impact as yet..
Oxford, UK - 1 February, 2022: Oxford Biomedica plc (LSE:OXB) ("Oxford Biomedica" or "the Company"), a leading gene and cell therapy group, announces that it was informed on Monday 31 January by Sio Gene Therapies (Sio) that Sio intends to return the global rights for AXO-Lenti-PD and that they intend to cease work on this gene therapy programme in Parkinson's Disease. This follows Sio's announcement yesterday about the resignation of their CEO where Sio also indicated a constraint on resource requirements that has caused Sio to deprioritise the programme. All rights shall be returned to Oxford Biomedica at no cost to the Company.
Current status of programme
Sio is currently conducting a Phase 2 SUNRISE-PD trial with AXO-Lenti-PD. In October 2020, Sio announced positive six-month follow up data from the second cohort of the trial, showing a 21-point mean improvement in UPDRS Part III 'OFF' score, a 40% improvement from baseline based on the two evaluable patients in the study. AXO-Lenti-PD continued to be shown to be well-tolerated with no treatment-related serious adverse events at six months. To date, six patients have been dosed in the Phase 2 study. Oxford Biomedica originally out-licensed AXO-Lenti-PD (previously named OXB-102) to Sio Gene Therapies (previously called Axovant Gene Therapies), in June 2018.
Oxford Biomedica announces update to agreement with Sio Gene Therapies
Oxford Biomedica announces that S io Gene Therapies intends to cease the license agreement for gene therapy programme in Parkinson’s disease
N egligible financial impact on Oxford Biomedica in the short and medium term
Non - core, legacy asset to be returned and out-licensed again in due course
Oxford, UK – 3 1 January , 2022: Oxford Biomedica plc (LSE:OXB) ("Oxford Biomedica" or "the Company"), a leading gene and cell therapy group, announced today that it was informed on Monday 31 January by Sio Gene Therapies (Sio) that Sio intends to return the global rights for AXO-Lenti-PD and that they intend to cease work on this gene therapy programme in Parkinson’s Disease. This follows Sio’s announcement today about the resignation of their CEO where Sio also indicates a constraint on resource requirements that has caused Sio to deprioritise the programme. All rights shall be returned to Oxford Biomedica at no cost to the Company.
Rns…someone’s working late tonight. No loss of revenue so may not have much impact on the sp.
Some interesting trades after time, any thoughts?
And up she goes.. some multiple reasonable sized buys going through.
Hi Kern,
The CEO leaving at this time definitely raises the question “why”. Homology is haemorrhaging money and it’s share price has only gone one way for years. Appreciate that OXB now have a manufacturing facility in America but at what cost?
973 trades as I write this and the sp is static for a normally very volatile share !
It’s probably just me but I have fallen out of love with this share now. I only have 25% of my holding left but if the rot continues that’s going too.
As you say hopefully reached bottom now but never envisaged that we would be sub £10 let alone this price.
Keep the faith :-(
I dread saying it but it seems as if this is the bottom, especially if the placing was at this price, but unless there is something in the pipeline we don't know about it is hard to see what will take this back to previous heights. Has OXB overextended itself in the eyes of the market? Why did the CEO choose now to leave? What is the financial impact of the vaccine going forward?
Questions, questions, though I am jaundiced by being nearly 20% down on a purchase within 10 days!
Matthew Treagus, Chief Information Officer, has purchased 594 ordinary shares of 50p each ("Ordinary Shares") in the Company on 28 January 2022 on the London Stock Exchange at a price of 841.7p. Even he doesn’t know what is going on ;-)
Very quiet here today . I think most expected and hoped for a bounce but the sp seems to be held back as usual. In the scheme of things Homology was not a big purchase but unfortunately Oxb still had to have a placing and loan to purchase 80% of it. This has lost 50% of its value recently. If it wasn’t for the vaccine production I dread to think where we would be.
Let’s hope that Homologys’ fortunes can turn around and it can start paying for itself.
It’s a mystery. There are some big shareholders such as Vulpes who must be livid at the drop. Perhaps the perfect storm….the markets are in the doldrums and many pharma have faired badly and perhaps it the sp has been manipulated with the automated trades?
Perhaps a good bounce later today but where this is going over the next few months is anyone’s guess?
A near 50% drop for a 5% placing seems like the sort of script I'd watch on Hollyoaks.
Is there bad news in the pipeline coming from elsewhere or is this how the market works.
I'd give anyone money for 5% of an asset if they devalue it by 50% for no real reason other than me buying 5%.
Guess I'm ill informed or does anyone else think it's a bit of an overreaction?